Charles River Laboratories, which contracted with BioVaxys, evaluated the antivirus immune response elicited by BVX-0320 by measuring the development of antibodies to the protein that binds the virus to human cells. Two injections of BVX-0320 along with the immunological adjuvant QS21 were given to 28 mice at four dosage levels. At week six, 96.4% developed positive antibody responses. Mice that received the QS21 adjuvant without BVX-0320 developed no antibody responses.

The companies are continuing to collect experimental data to determine the antibody levels induced by each dose of the vaccine and measure T-cell responses. Results are anticipated next month. Upon completion, BioVaxys plans to pursue regulatory approval for a phase I study of BVX-0320 in humans.

Pfizer, BioNTech finalize supply deal with EU for COVID-19 vaccine
Pfizer and BioNTech, developers of BNT162b2, a messenger RNA-based SARS-CoV-2 vaccine candidate, have reached an agreement with the European Commission...

Pfizer, BioNTech tout positive results for COVID-19 vaccine
Pfizer and BioNTech have released results from a phase III clinical trial evaluating their messenger RNA-based vaccine candidate, BNT162b2, demonstrating...

ImmunityBio COVID-19 vaccine shows positive clinical results
ImmunityBio has demonstrated that antigens from its bivalent adenovirus-based vaccine candidate are recognized by SARS-CoV-2 reactive human T cells in...

If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...

ABL Europe collaborates on SARS-CoV-2 vaccine
ABL Europe in France is collaborating with the University Clinic of Tuebingen and Prime Vector Technologies of Germany on a viral vector SARS-CoV-2 vaccine.